-
Progress in Hematology 1964
-
International Journal of Molecular... Dec 2022Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible for erythropoiesis. In addition to facilitating red blood cell production, EPO... (Review)
Review
Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible for erythropoiesis. In addition to facilitating red blood cell production, EPO has pluripotent potential, such as for cognition improvement, neurogenesis, and anti-fibrotic, anti-apoptotic, anti-oxidative, and anti-inflammatory effects. In human retinal tissues, EPO receptors (EPORs) are expressed in the photoreceptor cells, retinal pigment epithelium, and retinal ganglion cell layer. Studies have suggested its potential therapeutic effects in many neurodegenerative diseases, including glaucoma. In this review, we discuss the correlation between glaucoma and EPO, physiology and potential neuroprotective function of the EPO/EPOR system, and latest evidence for the treatment of glaucoma with EPO.
Topics: Humans; Erythropoietin; Receptors, Erythropoietin; Glaucoma; Epoetin Alfa; Retinal Ganglion Cells
PubMed: 36555679
DOI: 10.3390/ijms232416038 -
Journal of Neurochemistry Aug 2013In Friedreich ataxia (FRDA), several candidate substances including erythropoietin (EPO) focus on increase in the amount of frataxin and aim to counteract the... (Review)
Review
In Friedreich ataxia (FRDA), several candidate substances including erythropoietin (EPO) focus on increase in the amount of frataxin and aim to counteract the consequences of frataxin deficiency. Evidence for recombinant human erythropoietin (rHuEPO) in FRDA is based on in vitro studies using mouse neuronal cell lines, human fibroblasts, cardiomyocytes, and primary lymphocytes from FRDA patients or control subjects which showed a dose-dependent increase of frataxin after incubation with different erythropoietins. The mechanism by which EPO induces frataxin increase remains to be elucidated, but may involve post-transcriptional and/or post-translational modifications of frataxin or alterations in frataxin half-life and metabolism. In vivo data on rHuEPO's ability to increase frataxin in FRDA patients is contradictory as studies on the effect of EPO derivatives in FRDA differ in treatment regimen, sample size, and duration. Open-label studies indicate for sustained frataxin increase, decrease of oxidative stress, and clinical improvement in FRDA patients after administration of rHuEPO. Two randomized controlled studies found acceptable safety and tolerability of EPO derivatives in FRDA. Secondary outcome measures, however, such as frataxin up-regulation and clinical efficacy were not met. This review will focus on (i) pre-clinical work on erythropoietins in FRDA and (ii) clinical studies in FRDA patients exposed to erythropoietins.
Topics: Animals; Epoetin Alfa; Erythropoietin; Friedreich Ataxia; Humans; Iron-Binding Proteins; Recombinant Proteins; Frataxin
PubMed: 23859343
DOI: 10.1111/jnc.12301 -
The New England Journal of Medicine May 2020
Topics: Epoetin Alfa; Erythropoietin; Humans; Infant; Infant, Newborn; Infant, Premature; Neuroprotection
PubMed: 32374968
DOI: 10.1056/NEJMc2002493 -
The New England Journal of Medicine May 2020
Topics: Epoetin Alfa; Erythropoietin; Humans; Infant; Infant, Newborn; Infant, Premature
PubMed: 32374969
DOI: 10.1056/NEJMc2002493 -
Attualita Di Ostetricia E Ginecologia 1964
-
Annals of Internal Medicine Jan 1958
Topics: Epoetin Alfa; Erythrocytes; Erythropoietin
PubMed: 13488231
DOI: 10.7326/0003-4819-48-1-207 -
British Medical Journal Apr 1964
Topics: Epoetin Alfa; Erythropoietin; Humans; Recombinant Proteins
PubMed: 14113813
DOI: 10.1136/bmj.1.5390.1060 -
The Journal of Reproductive Medicine May 2001Erythropoietin, a glycoprotein hormone, is synthesized predominantly in the kidney and secreted by renal cortical interstitial cells in response to tissue hypoxia.... (Review)
Review
Erythropoietin, a glycoprotein hormone, is synthesized predominantly in the kidney and secreted by renal cortical interstitial cells in response to tissue hypoxia. Erythropoietin is the main regulator of the production of red blood cells. It functions in the recruitment and differentiation of erythroid progenitor cells and aids in their maintenance and survival. Erythropoietin also stimulates the synthesis of hemoglobin. In the last 15 years, the ready availability of recombinant human erythropoietin (r-HuEPO, epoetin alfa) has permitted the clinical investigation and application of this hormone to the treatment of anemia in various patient populations. Epoetin alfa has been shown to accelerate erythropoiesis and reduce allogeneic blood transfusion in major elective, noncardiac, nonvascular surgery and in certain anemic patients with chronic renal failure, nonmyeloid malignancies and human immunodeficiency virus infection. In addition to improving hematologic parameters, epoetin alfa therapy can enhance health-related quality of life in these patients. The success of epoetin alfa in treating anemia in other surgical populations suggests that it may be of benefit in treating the perioperative anemia that is highly prevalent in gynecologic surgery patients. Further investigation of the use of epoetin alfa in patients undergoing gynecologic surgery would increase awareness of its benefits for this patient population.
Topics: Anemia; Elective Surgical Procedures; Epoetin Alfa; Erythropoiesis; Erythropoietin; Female; Gynecologic Surgical Procedures; Hematinics; Humans; Perioperative Care; Quality of Life; Recombinant Proteins
PubMed: 11396386
DOI: No ID Found -
Lekarsky Obzor 1964